Angelini Ventures opens 2025 with two investments in high-potential sectors

Angelini Ventures, the corporate venture capital firm of Angelini Industries, continues its investment strategy aimed at backing innovative startups in the health sector. The most recent deals involve Neumirna Therapeutics - a Danish biotech focused on developing RNA-based therapies for the treatment of neurological diseases - and Nobi Smart Lights, a Belgian company active in the AgeTech sector. Although operating in different fields, both companies share a pioneering approach and an international vocation: Neumirna is positioned in a rapidly evolving biotech segment driven by the most advanced scientific discoveries, while Nobi, already expanding in the U.S. and U.K. markets, aims to respond to the challenges posed by the aging global population.

For the first time Angelini Ventures has, in both investments, the role of co-lead.

The co-lead role involves a decisive function in strategic management and coordination of the investment and includes active and structured involvement in mobilizing additional partners to complete the funding. 

This achievement reflects the growing maturity of Angelini Ventures and its ability to exercise a catalytic function by identifying high-potential investments. Angelini Ventures also plays an active role in the governance of its portfolio companies, offering direct, structured and ongoing support to achieve growth and innovation objectives. Finally, the company has consolidated its strategic presence within the two target companies by obtaining an active role on their respective boards of directors.

The €20 million investment in the Series A round, co-led by Angelini Ventures and Invivo Partners, with participation from Innovestor Life Science Fund and other existing investors, represents a major milestone in Neumirna Therapeutics' growth path.

Founded in 2020, Neumirna was established with the goal of revolutionizing treatment paradigms for neurological disorders (CNSs) by harnessing the potential of microRNAs-small molecules of noncoding RNA. Also known as "molecular switches," these regulators of gene expression are the focus of growing scientific interest: their importance was recognized internationally in 2024 with the award of the Nobel Prize in Medicine to the scientists who discovered and characterized their fundamental properties.

Using an innovative technology platform, Neumirna develops targeted therapies to address neurological disorders that still lack effective treatments, such as drug-resistant epilepsy and Parkinson's disease.

Central to Neumirna's pipeline is NMT.001, an antisense drug candidate designed to interact with specific microRNA sequences and modulate biological processes underlying complex neurological disorders. Preclinical data have shown that NMT.001 can significantly reduce seizures, both spontaneous and pharmacologically induced, offering new therapeutic perspectives for patients living with these debilitating conditions.

With the new funds, Neumirna will be able to strengthen its research and development activities, further improve its technology platform, and accelerate the clinical development of NMT.001.

The investment in Nobi Smart Lights marks Angelini Ventures' debut in AgeTech, technology solutions for an increasingly long-lived population. The funding round, co-led by Angelini Ventures and Nexus NeuroTech Ventures, with strategic support from Japanese investor 15th Rock, resulted in a €35 million Series B financing (more than €50 million, including previous rounds) intended to support the company's global expansion and technology development.

The deal has seen strong interest from the investment community, exceeding initial expectations and underscoring the transformative potential of the target company's proposed solutions. This market response not only reflects the attractiveness of the AgeTech sector, but also highlights the growing demand for advanced technologies to improve the quality of life of older people and provide greater safety and autonomy.

Nobi Smart Lights has developed a cutting-edge technology solution that integrates elegant and functional design with advanced artificial intelligence (AI): a life-saving lamp that can detect falls in real time and drastically reduce intervention time-from 68 to just 4 minutes. Nobi's technology is not only limited to detecting incidents, but also offers advanced features to analyze triggers for events, identify risky behaviors, and activate preventive measures, supporting both caregivers and patients, whose safety and quality of life can benefit from concrete and measurable improvement.

Investments in Neumirna Therapeutics and Nobi Smart Lights highlight Angelini Ventures' ability to intercept opportunities in high-impact segments that can address unmet medical needs and make a contribution to improving quality of life.